

Technology Pipeline

BIOLOGIC

Anschutz

Innovations

Where we are located

CU ANSCHUTZ MEDICAL CAMPUS

The University of Colorado Anschutz is a world-class medical destination at the forefront of transformative science, medicine, education and patient care. The campus encompasses the University of Colorado health professional schools, more than 60 centers and institutes, and two nationally ranked independent hospitals - UCHealth University of Colorado Hospital and Children's Hospital Colorado - that treat more than two million adult and pediatric patients each year. Innovative, interconnected and highly collaborative, the CU Anschutz delivers life-changing treatments, patient care and professional training and conducts world-renowned research fueled by over $704 million in research grants.

For more information, visit **www.cuanschutz.edu**.

Peptide *Antibody Based* *Large Molecule* *Nucleotide*

AVAILABLE **LIMITED AVAILABILITY** **PARTNERED**

Basic Research	Biologic Discovery				Biologic Development			Clinical Trials	
Basic Research	Identify Target	Assay Dev.	Synthesis & Purification	Animal Models	Characterization	ADME	Toxicity	Pilot Scale	Clinical Trials

PRINCIPAL INVESTIGATOR (PI)

Cardiology

Kimberley Bruce	**25219**	**APOC-II MIMETIC PEPTIDES IN LIPOSOMES**
Mary Weiser-Evans	**25295**	**RESTORING VASCULAR INTEGRITY WITH PLGA-ENCAPSULATED PTEN NANOPARTICLES TO PREVENT RESTENOSIS AND ATHEROSCLEROTIC PROGRESSION**

Dermatology

Alexander Horswill	**24-211**	**PEPTIDE INBIBITOR OF STAPH AUREUS**
Kenneth Liechty	**3681**	**MICRORNA FOR WOUND HEALING**
Xiao-Jing Wang	**3302H**	**PTD-SMAD7 THERAPEUTIC**

Peptide *Antibody Based* *Large Molecule* *Nucleotide*

AVAILABLE **LIMITED AVAILABILITY** **PARTNERED**

Basic Research | Biologic Discovery | Biologic Development | Clinical Trials

Basic Research | Identify Target | Assay Dev. | Synthesis & Purification | Animal Models | Characterization | ADME | Toxicity | Pilot Scale | Clinical Trials

Endocrine/Metabolism

PRINCIPAL INVESTIGATOR (PI)

Aaron Michels	3588H	INSULIN B MIMOTOPE - T1D
David Wagner	26-006	PEPTIDE AUTOANTIGEN - T1D
Tunuguntla Kumar	5155	RECOMBINANT FSH FOR ART
Yuwen Zhu	25-165	TARGETING GPR182 TO TREAT OBESITY AND NASH
John C Hutton *(Deceased)*	1673	PEPTIDE AUTOANTIGEN - T1D
Jan Kraus	3197	TREATMENT OF HOMOCYSTINURIA
Jan Kraus	4865	COMBINE WITH OTHER HOMOCYSTINURIA

About our resources

COMPUTATIONAL CHEMISTRY & BIOLOGY CORE

The University of Colorado Anschutz Computational Chemistry and Biology Core Facility provides a wide array of advanced tools and services for computational-based simulations and modeling of chemical and biological systems. Located in the new Skaggs School of Pharmacy and Pharmaceutical Sciences building, the CCB Core offers specialized expertise to researchers in both academia and the biotech/pharmaceutical industry to develop and test hypotheses in silico before executing costly experimental methodologies, reduce the time and costs involved in cutting-edge research, target validation, and novel therapeutic development among other services.

For more information, visit **www.pharmacy.cuanschutz.edu/research/core-facilities/computational-chemistry-and-biology-core-facility**

Peptide *Antibody Based* *Large Molecule* *Nucleotide*

AVAILABLE **LIMITED AVAILABILITY** **PARTNERED**

Basic Research | Biologic Discovery | Biologic Development | Clinical Trials

Basic Research | Identify Target | Assay Dev. | Synthesis & Purification | Animal Models | Characterization | ADME | Toxicity | Pilot Scale | Clinical Trials

PRINCIPAL INVESTIGATOR (PI)

Immunology

David H Wagner	2376	CD154 PEPTIDE
David H Wagner	5945	CD40 PEPTIDE INHIBITOR - CANINE AUTOIMMUNE DISEASE
John C Cambier	2233	ANTI-CD79 MAB - RA AND LUPUS
V. Michael Holers	2545	C3 ANTIBODIES
V. Michael Holers	3638	MAP44 ANTIBODY

Infectious Disease

Olivia Rissland	24-292	APPLICATION AND DEVELOPMENT OF SECOND-GENERATION 2A PEPTIDES
Robert Hodges *(Deceased)*	1323	ALPHA-HELICAL ANTIMICROBIAL PEPTIDES

Inflammatory

Suzhao Li	26-091	ALPHA-HELICAL ANTIMICROBIAL PEPTIDES

Peptide *Antibody Based* *Large Molecule* *Nucleotide*

AVAILABLE **LIMITED AVAILABILITY** **PARTNERED**

Basic Research | Biologic Discovery | Biologic Development | Clinical Trials

Basic Research | Identify Target | Assay Dev. | Synthesis & Purification | Animal Models | Characterization | ADME | Toxicity | Pilot Scale | Clinical Trials

Neurology

PRINCIPAL INVESTIGATOR (PI)

Huntington Potter	4121	GM-CSF PEPTIDE MIMETIC - NEURODEGENERATION & COGNITION
Ulli Bayer	2736	NEUROPROTECTIVE PEPTIDE
Ulli Bayer	1933	CAMKII PEPTIDE
Paco S Herson	3191	TRPM2 PEPTIDE INHIBITORS
Paco S Herson	4027	NEUROPROTECTIVE PEPTIDE
Paco S Herson	5209	PEPTIDE INHIBITORS OF TRPM2
Ulli Bayer	25175	CAMKII PEPTIDE INHIBITORS FOR NEUROLOGICAL DISEASE
Ulli Bayer	25176	CAMKII PEPTIDE INHIBITORS FOR DOWN SYNDROME
Ulli Bayer	25177	CAMKII PEPTIDE INHIBITORS FOR NEUROLOGICAL DISEASE

About our resources

CENTER FOR DRUG DISCOVERY

The University of Colorado Anschutz Center for Drug Discovery supports drug discovery and development of small molecules, peptides, proteins and antibody-based therapeutics through services like assay development, high-throughput and high-content screening, medicinal chemistry for each stage of development, and pharmacology, including PK, PD, and toxicology. Directed by Dr. Dan LaBarbera, the Center for Drug Discovery also offers additional unique models for microtissues and organoids through 2D and 3D printing as well as phenotypic cell painting.

Translational Phase:

From Discovery to Bedside



For more information, visit **www.pharmacy.cuanschutz.edu/drug-discovery**.

To see facility in the news, go to **www.youtube.com/watch**.


Peptide
Antibody Based
Large Molecule
Nucleotide
AVAILABLE
LIMITED AVAILABILITY
PARTNERED
Basic Research
Biologic Discovery
Biologic Development
Clinical Trials
Basic Research
Identify Target
Assay Dev.
Synthesis & Purification
Animal Models
Characterization
ADME
Toxicity
Pilot Scale
Clinical Trials
Oncology/Hematology
PRINCIPAL INVESTIGATOR (PI)
Benjamin Bitler
5591
OVARIAN CANCER
Charles Dinarello
4293
CHIMERIC IL-37/IGG
Clayton Smith
6191H
AML THERAPY
John Stewart (Deceased)
1445H
ANTI-BRADYKININ PEPTIDES
Rajeev Vibhakar
0082
SARCOMA
Rui Zhao
24-156
PEPTIDE INHIBITOR OF EYA3
Traci Lyons
5633
ANTI-SEMA7A MAB FOR BREAST CANCER TREATMENT
Traci Lyons
5954H
ANTI-SEMA7A MAB - BREAST CANCER
Yubin Miao
6192
RADIOLIGAND THERAPY FOR METASTATIC MELANOMA
Zhirui Wang
26-084
CD38 IMMUNOTOXIN FOR ALL
Zhirui Wang
4936H
CCR4-IL2 BISPECIFIC IMMUNOTOXIN - CUTANEOUS T-CELL LYMPHOMA
Zhirui Wang
6201H
CD47 IMMUNOTOXIN - BREAST CANCER
Zhirui Wang
6218H
CCR4 IMMUNOTOXIN - TNBC

Peptide *Antibody Based* *Large Molecule* *Nucleotide*

AVAILABLE **LIMITED AVAILABILITY** **PARTNERED**

Basic Research | Biologic Discovery | Biologic Development | Clinical Trials

Basic Research | Identify Target | Assay Dev. | Synthesis & Purification | Animal Models | Characterization | ADME | Toxicity | Pilot Scale | Clinical Trials

PRINCIPAL INVESTIGATOR (PI)

Ophthalmology

Ram Nagaraj	25-106	PEPTIDE - AMD
Ram Nagaraj	5122H	PEPTIDES - GALUCOMA
Udaya Kompella	2886	TUMSTATIN BASED THERAPY
Udaya Kompella	3086	RECOMBINANT LEDGF

Rheumatology

Kristine Kuhn	5449	RUMINOCOCCUS SUBDULOGRANULUM: BIOMARKER & THERAPEUTIC TARGET FOR RA

Women's Health

Thomas Jansson	25-159	TREATMENT FOR PREMATURITY
Tunuguntla Kumar	5135	RECOMBINANT FSH FOR ART

About us

CU ANSCHUTZ INNOVATIONS

We bring together industry partners, entrepreneurs, and investors to help CU Researchers create biomedical technology that improves the quality of life worldwide. With expertise in patents, copyrights, and licensing, CU Anschutz Innovations translates discovery into impact through transparent, flexible, best practice intellectual property management services.

Located on University of Colorado Anschutz Medical Campus, Innovations provides access to an extensive portfolio of biomedical technologies, clinical validation opportunities, and resources for startup development.

Let's start a conversation.

CONTACT

David Wang
Assistant Director of BD & Licensing
CU Anschutz Innovations
University of Colorado Anschutz
david.d.wang@cuanschutz.edu

Anschutz

Innovations

Anschutz Health Sciences Building
1890 N. Revere Ct., Suite 6202
Aurora, CO 80045

(303) 724-3720
innovations@cuanschutz.edu

cuanschutz-innovations/

@cuanschutz-innovations

WEBSITE Scan to view our website and to learn more about how we can best support you > **cuanschutz.edu/innovations**